Pfizer and BioNTech have asked US regulators to authorise emergency use of their COVID-19 vaccine for children aged 5 to 11.
The US Food and Drug Administration has set a date of October 26 for its panel of outside advisers to meet and discuss the application, making it possible for children in this age group - numbering around 28 million - to begin receiving the two-dose Pfizer/BioNTech vaccine shortly afterwards.
"With new cases in children in the US continuing to be at a high level, this submission is an important step in our ongoing effort against COVID19," Pfizer wrote on Twitter.
The vaccine already has won US emergency use authorisation in teens aged 12 to 15 and is fully approved by regulators for people aged 16 and up.
The Pfizer/BioNTech vaccine is one of three in use in the United States, along with the two-dose Moderna vaccine and the single-dose Johnson & Johnson version, neither of which has won full regulatory approval for any age group.
A rapid authorisation of the Pfizer/BioNTech vaccine in young kids could help mitigate a potential surge of cases in the coming weeks and months, with schools open nationwide and colder weather driving activities indoors.
If given regulatory authorisation, the two-dose vaccine would become the first COVID-19 shot made available to children 5 to 11 in the United States.
The Pfizer/BioNTech vaccine has been shown to induce a strong immune response in 5 to 11 year olds in a 2,268-participant clinical trial, the companies said on September 20.
The two drugmakers are also testing the vaccine in children aged 2 to 5 years old and those aged 6 months to 2 years, with data expected in the fourth quarter.
The vaccine could be ready for roll out as early as November pending approval from federal regulatory health agencies, White House COVID-19 response coordinator Jeffrey Zients said on CNN.
Once the authorization is granted, Zients said: "We are ready. We have the supply. We're working with states to set up convenient locations for parents and kids to get vaccinated including paediatricians' offices and community sites."
The United States leads the world in COVID-19 cases and deaths.
Children currently make up about 27 per cent of all US coronavirus cases and an increasing percentage of hospitalisations, according to the American Academy of Pediatrics.
That reflects the high contagiousness of the coronavirus Delta variant among unvaccinated people.
While children are less susceptible to severe COVID-19, they can spread the virus to others, including vulnerable populations more at risk of severe illness.
A Pfizer spokesperson said the application to the FDA has been completed.